Technical Analysis for ARDX - Ardelyx, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Outside Day | Range Expansion | 0.77% | |
| Wide Bands | Range Expansion | 0.77% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -2.12% | |
| Inside Day | Range Contraction | -2.12% | |
| Wide Bands | Range Expansion | -2.12% |
| Alert | Time |
|---|---|
| Possible NR7 | about 19 hours ago |
| Possible Inside Day | about 19 hours ago |
| Gap Up Partially Closed | about 23 hours ago |
| Gapped Up (Partial) | about 23 hours ago |
| Up 3% | about 23 hours ago |
Get a Trading Assistant
- Earnings date: 06/14/2024
Ardelyx, Inc. Description
Ardelyx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics to treat cardio-renal, gastrointestinal (GI), and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal, GI, and metabolic diseases. Ardelyx, Inc. has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Phosphates Gastrointestinal Kidney Disease Metabolic Disease Chronic Kidney Disease End Stage Renal Disease Renal Disease Stage Renal Disease Constipation Irritable Bowel Syndrome Molecule Therapeutics Rockwell Medical Hyperphosphatemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.13 |
| 52 Week Low | 3.16 |
| Average Volume | 5,735,652 |
| 200-Day Moving Average | 6.10 |
| 50-Day Moving Average | 7.54 |
| 20-Day Moving Average | 7.32 |
| 10-Day Moving Average | 8.19 |
| Average True Range | 0.50 |
| RSI (14) | 53.49 |
| ADX | 25.37 |
| +DI | 26.08 |
| -DI | 23.02 |
| Chandelier Exit (Long, 3 ATRs) | 7.83 |
| Chandelier Exit (Short, 3 ATRs) | 7.73 |
| Upper Bollinger Bands | 9.34 |
| Lower Bollinger Band | 5.30 |
| Percent B (%b) | 0.63 |
| BandWidth | 55.13 |
| MACD Line | 0.23 |
| MACD Signal Line | 0.14 |
| MACD Histogram | 0.0816 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.17 | ||||
| Resistance 3 (R3) | 8.20 | 8.12 | 8.11 | ||
| Resistance 2 (R2) | 8.12 | 8.04 | 8.11 | 8.09 | |
| Resistance 1 (R1) | 7.99 | 7.99 | 7.95 | 7.96 | 8.08 |
| Pivot Point | 7.91 | 7.91 | 7.90 | 7.90 | 7.91 |
| Support 1 (S1) | 7.78 | 7.83 | 7.74 | 7.75 | 7.62 |
| Support 2 (S2) | 7.70 | 7.78 | 7.69 | 7.61 | |
| Support 3 (S3) | 7.57 | 7.70 | 7.59 | ||
| Support 4 (S4) | 7.54 |
